I'm not so daffy as to believe that your or anyone's right to an opinion can be negated by some logic. You've already expressed your opinions well, and regarding GALT's clinical trial shortcomings your critiques I find valid for the most part. What ticks me is manor, not matter.
The way the world works it would take a battle royale to unseat Dr. Traber et al. As Biotech2010 (on 10/4/16) put it, regarding the CX protocol "nothing you say is going to change the chosen path".
But unlike Biotech2010 and others I feel the present management is presently good with its MDs. They
are well aware the stakes are high on all counts. I've known several academic MDs and they all are motivated by making a mark in Medicine.
My hope is the renewed big investor Uihlein is keyed to backing
a major medical breakthrough.
J.
News 
Market Data 
Discover 
